Navigation Links
ProMIS Neurosciences Announces Appointment of Anthony Giovinazzo to its Board of Directors

ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Anthony J. Giovinazzo, MBA, to its Board of Directors, effective immediately.

“I first met Anthony over twenty years ago, working together on an Alzheimer’s diagnostics opportunity” stated Eugene Williams, ProMIS Executive Chairman. “He and I have been talking about a shared commitment to making a difference in Alzheimer’s for a long time. After the outstanding job that Anthony did at Cynapsus, for both Parkinson’s patients and shareholders, he has many alternatives. We are thrilled that he has chosen to apply his talents and energy to ProMIS”.

Anthony Giovinazzo is currently President and CEO of Sunovion CNS Development Canada ULC. As President and CEO of Cynapsus Therapeutics from 2009 through 2016 he led the successful purchase of Cynapsus by Sunovion Pharmaceuticals, a member of the Dainipon Sumitomo Pharma group of Japan. At Cynapsus, Anthony led the successful development of APL 130277 (a sublingual strip of apomorphine) through to late stage Phase 3 studies and was responsible for Cynapsus up-listing from the TSX Venture exchange to the TSX and then the NASDAQ.

“I am delighted to join the Board of Directors of ProMIS Neurosciences,” stated Mr. Giovinazzo. “Having devoted most of my career to the development and commercialization of therapies for neurodegenerative disease, I look forward to leveraging my experience to support the Company as it develops innovative, precision medicine therapeutics for Alzheimer’s disease and ALS”.

About Anthony Giovinazzo, MBA.
Anthony J. Giovinazzo has over thirty-eight years of professional experience. His first seven years were spent as an international corporate tax specialist primarily in multinational conglomerates. Over the subsequent eight years Anthony worked in Fortune 100 investment banking and private equity. For the last twenty-three years he worked exclusively on the discovery, development and commercialization of neurodegenerative disease therapeutics. His primary areas of focus have been Alzheimer’s, Parkinson’s and neuropathic pain.

Since October 2016 he has been the President and CEO of Sunovion CNS Development Canada ULC., a successor company to Cynapsus Therapeutics Inc., which was purchased by Sunovion Pharmaceuticals Inc., a member of the Dainipon Sumitomo Pharma group of companies of Japan. He was President, CEO and a Director of Cynapsus Therapeutics Inc. from 2009 to 2016 and was one of the three original inventors and patent holders of the Cynapsus Parkinson’s focussed technology. Under his leadership the company successfully developed APL 130277 (a sublingual strip of apomorphine for OFF episodes) through to late stage Phase 3 studies. In addition, Anthony led the up-listing of Cynapsus from the TSX Venture exchange to the TSX and then the NASDAQ, attracting bulge bracket investment banks and some of the largest institutional life science investors in the USA. The sale of Cynapsus to Sunovion in 2016 resulted in a 120% premium to market price (CDN$841 million) via an all cash M&A transaction.

Mr Giovinazzo is the co-author of several peer reviewed papers and author of several papers on strategic and financing issues in the biopharmaceutical industry. He was a finalist in the E&Y Entrepreneur of the Year (2014) for Ontario Canada. He is a Chartered Director and Audit Committee Certified, both from The Directors College, a degree granting affiliate of Mc Master University, Hamilton Canada. He also has completed the Leadership and Strategy in Pharmaceuticals and Biotech, in 2006 from Harvard Business School, Boston, MA; a Masters of Business Administration from IMD, Geneva Switzerland in 1986; Graduate Certificate Studies in Canadian Law Osgoode Hall Law School, York University, Toronto, in 1984; and his Bachelor of Arts in Economics and Accounting at McMaster University in 1978.

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:

Like us on LinkedIn

or contact

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. ProMIS Neurosciences issues white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach”
2. ProMetics PBI-4050 receives promising innovative medicine designation from the UK MHRA for the treatment of Alström Syndrome
3. ProMIS Neurosciences Declares PMN 310 its First Lead Product for Development in Alzheimer’s Disease
4. SRI Awarded $150 Million NIAID-DAIDS Contract to Provide Development and Manufacturing Support for Promising HIV-Prevention Products
5. ProMIS Neurosciences Announces Novel Alzheimer’s Disease Therapeutic Candidates Block the Neurotoxicity of Prion-Like Forms of Amyloid Beta
6. Bioengineering Innovations Show Promise for Improving Treatments and Drug Delivery
7. ProMIS Neurosciences announces five novel Alzheimer’s disease therapeutic candidates block spreading of toxic prion-like forms of Amyloid beta
8. Promising New Prostate Cancer Tests On The Horizon - Dr. David Samadi
9. PrecisionAg® Media’s New Vision Accelerates the Promise of Technology-Driven Agriculture
10. ProMIS Neurosciences Announces Identification of a Fourth Novel Therapeutic Target for Alzheimer’s Disease
11. Communications Among Most Promising Applications for Game-Changing Graphene
Post Your Comments:
(Date:1/24/2019)... ... January 22, 2019 , ... Controlled Contamination Services is pleased to announce three ... of these valuable new team members will support its growing operation across the US ... CCS scales its business. This addition will enable CCS to widen its reach and ...
(Date:1/24/2019)... , ... January 22, 2019 , ... ... each trial has its own set of assumptions, and RFP creation and management ... evaluating bids is like comparing apples to oranges. These challenges can ultimately lead ...
(Date:1/21/2019)... (PRWEB) , ... January 21, 2019 , ... ... their newest product line, SporActiv™, for the industrial and institutional cleaning market. MDG’s ... of residential and commercial cleaning needs. Applications include odor control, floor and tile ...
(Date:1/20/2019)... ... January 17, 2019 , ... Consumers are directing healthcare in ... physicians. That's changing as many services now exist for patients to order tests ... totaled $208 million in 2018, according to Kalorama Information’s new report, The ...
Breaking Biology Technology:
(Date:2/6/2019)... ... February 05, 2019 , ... Amino Labs, ... partnered with MindFuel, a leading organization in educational science, technology, engineering and math ... Labs has pioneered a syn-bio starter kit for teachers – the Amino ...
(Date:2/2/2019)... FRANCISCO (PRWEB) , ... January 31, 2019 , ... ... leader in microbial genomics, has awarded microbiome research support in study design, planning, ... Behr, PhD, HCLD, Professor of Obstetrics and Gynecology, and Dr. Sara Vaughn, MD, ...
(Date:2/2/2019)... SAN FRANCISCO (PRWEB) , ... February 01, 2019 ... ... granted ISO 15189 Accreditation for Clinical Testing Laboratories by A2LA, which establishes requirements ... to an international standard. The laboratory is already CLIA-licensed as well as College ...
Breaking Biology News(10 mins):